SFI
BCAX

Susquehanna Fundamental Investments’s Bicara Therapeutics BCAX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$272K Buy
+9,173
New +$205K 0.01% 660

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Susquehanna Fundamental Investments's BCAX Position: Q2 2026 in Review

Susquehanna Fundamental Investments opened a new position in Bicara Therapeutics (BCAX) in Q2 2026: 9,173 shares worth $272K. The stake represents 0.01% of the portfolio and ranks #660 among its holdings.

172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Susquehanna Fundamental Investments held 9,173 shares of Bicara Therapeutics worth $272K as of Q2 2026.
  • Bicara Therapeutics was a new Susquehanna Fundamental Investments position in Q2 2026.
  • Bicara Therapeutics made up 0.01% of Susquehanna Fundamental Investments's portfolio in Q2 2026, its #660 holding.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2026, filed 14 Aug 2026.